Active Rheumatoid Arthritis

Immunology
4
Pipeline Programs
3
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Bristol Myers Squibb
ORENCIAApproved
abatacept
Bristol Myers Squibb
Selective T Cell Costimulation Modulator [EPC]iv (infusion)2005

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
1 program
1
1
AbataceptPhase 31 trial
Active Trials
NCT00420199Completed50Est. May 2010
Astellas
AstellasChina - Shenyang
1 program
1
CDP870Phase 31 trial
Active Trials
NCT02586246Completed86Est. May 2013
UP
UCB PharmaBelgium - Brussels
1 program
1
CDP870Phase 3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstellasCDP870
Bristol Myers SquibbAbatacept

Clinical Trials (2)

Total enrollment: 136 patients across 2 trials

Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870

Start: Jan 2011Est. completion: May 201386 patients
Phase 3Completed

A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Start: May 2007Est. completion: May 201050 patients
Phase 3Completed

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space